Trials / Completed
CompletedNCT05057923
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- DreamTec Research Limited · Industry
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Accepted
Summary
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
Detailed description
Bacillus subtilis is regarded as safe organism by The Food and Drug Administration and it is presented in most food sources. Preliminary experiments have shown that the genetically engineered Bacillus subtilis can express and display receptor binding domain of spike protein of the SARS-COV2 on its spore coat, thus successfully induce the secretion of cytokines of human cells in vitro. Previous experiments also successfully demonstrated that a increased detection of neutralizing IgG and igM levels in mice after oral administrated with the Bacillus subtilis. This suggests that the transgenic spores of Bacillus subtilis have successfully activated the immune system, producing high-affinity neutralizing antibodies and memory B cells. Furthermore, no adverse effects were shown in all the mices. The engineered Bacillus subtilis will be further studied in a human trials through oral administration to test its safety and the immune effect resulted in human bodys.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Bacillus subtilis | Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment. |
Timeline
- Start date
- 2021-07-10
- Primary completion
- 2021-10-20
- Completion
- 2021-11-01
- First posted
- 2021-09-27
- Last updated
- 2023-05-31
- Results posted
- 2021-12-23
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT05057923. Inclusion in this directory is not an endorsement.